Madecassoside

What is it?

Madecassoside is one of the four principal triterpenoid saponins found in Centella asiatica (also known as cica or tiger grass), alongside asiaticoside, madecassic acid, and asiatic acid. It is a glycoside of madecassic acid and is considered the gentlest and most anti-inflammatory of the centella-derived actives. Madecassoside has been extensively studied for its wound healing, anti-inflammatory, and collagen-stimulating properties. In clinical dermatology, madecassoside has demonstrated the ability to reduce erythema, calm irritated skin, promote keratinocyte migration for faster wound closure, and stimulate type I collagen synthesis in fibroblasts. It inhibits NF-κB-mediated inflammatory signaling and reduces pro-inflammatory cytokines including TNF-alpha, IL-1β, and IL-6. Unlike some centella extracts that may vary in composition, purified madecassoside provides consistent, targeted anti-inflammatory and regenerative activity. It is water-soluble, pH-stable across a broad range, non-photosensitizing, and well-tolerated even by the most sensitive and reactive skin types. Typical concentrations in topical formulations range from 0.1% to 1%, with clinical benefits demonstrated at concentrations as low as 0.1%.

How It Works

1. 1

   Suppresses NF-κB Inflammation

   Blocks the NF-κB pathway to reduce TNF-alpha, IL-1β, and IL-6 — complementing PDRN's adenosine A2A anti-inflammatory signaling.

2. 2

   Stimulates Collagen via TGF-β

   Activates TGF-β signaling in fibroblasts to promote type I collagen synthesis alongside PDRN's collagen pathway.

3. 3

   Accelerates Wound Closure

   Promotes keratinocyte migration to speed re-epithelialization, while PDRN rebuilds the underlying dermal matrix.

4. 4

   Protects Against Oxidative Stress

   Scavenges reactive oxygen species that would otherwise damage newly synthesized collagen from PDRN treatment.

Role in PDRN

Madecassoside and PDRN form a powerful regenerative and anti-inflammatory duo that addresses tissue repair from complementary angles. PDRN activates the adenosine A2A receptor to stimulate fibroblast proliferation and collagen synthesis, while madecassoside promotes collagen production through a separate TGF-β-mediated pathway. This dual-pathway collagen stimulation can produce more robust structural repair than either ingredient alone. Both ingredients share strong anti-inflammatory mechanisms but act through different molecular targets: PDRN through adenosine receptor signaling and madecassoside through NF-κB suppression. Together, they provide comprehensive inflammatory control that is especially valuable for post-procedure recovery, where managing inflammation is critical for optimal healing outcomes. Madecassoside's keratinocyte migration-promoting effect complements PDRN's fibroblast-focused regeneration, ensuring both the epidermal and dermal layers heal efficiently.

Clinical Data

A 2008 study in the Journal of Investigative Dermatology demonstrated that madecassoside significantly promoted wound healing in both in vitro and in vivo models by enhancing collagen synthesis and keratinocyte migration. A 2012 study in Skin Pharmacology and Physiology confirmed madecassoside's ability to reduce UV-induced erythema and inflammation in human subjects. Research published in Phytomedicine (2014) showed that madecassoside inhibits NF-κB activation and reduces TNF-alpha production in a dose-dependent manner. When combined with PDRN in post-procedure settings, the dual anti-inflammatory and regenerative mechanisms have been observed to reduce recovery time and improve overall healing quality.